Recently, the therapeutic efficacy of an inhibitor against KRAS G12D mutated CRC was found to be increased by the combined use of anti-EGFR therapy, which blocked a feedback activation loop driven by EGFR-mediated wild-type RAS signaling [29]. Here, EGFR is linked to colorectal carcinoma.